Fact-checked by Grok 2 weeks ago

Expanded Disability Status Scale

The Expanded Disability Status Scale (EDSS) is a standardized clinical designed to measure the severity of disability in patients with (MS) by assessing neurological impairments across eight functional systems—pyramidal, cerebellar, , sensory, bowel and , visual, cerebral, and other—and overall ability. Scores range from 0 (normal neurological function with no disability) to 10 ( due to MS), in 0.5 increments, providing a quantifiable benchmark for disease impact. Developed by neurologist John F. Kurtzke, the EDSS evolved from his original Disability Status Scale (DSS), introduced in the to evaluate -related impairments, and was formally expanded in 1983 to offer finer gradations of while incorporating revised scoring for sensory and bowel/bladder systems. Each of the eight functional systems is graded from 0 (normal) to 5 or 6 (severe impairment), with the overall EDSS score derived from these grades for levels 0 to 4.0, emphasizing the most affected systems. From 4.5 to 9.5, the scale shifts focus to and , such as the distance a can walk without aid (e.g., 4.5 indicates fully but with moderate in multiple systems, while 7.0 signifies use for most distances). In clinical practice, neurologists administer the EDSS through physical examinations and patient reports to track MS progression, evaluate treatment responses, and determine eligibility for disease-modifying therapies or clinical trials, where scores above 6.5 often limit access due to advanced . Despite its widespread use as the primary outcome measure in MS studies for over four decades, the EDSS has faced for its heavy reliance on walking , potentially underrepresenting upper-body or cognitive impairments in non-ambulatory patients.

Introduction

Definition and Purpose

The Expanded Disability Status Scale (EDSS) is a clinician-rated ordinal scale designed to quantify the degree of neurological impairment and in patients with (MS). Developed as an expansion of earlier measures, it assigns scores from 0 (normal neurological function) to 10 (death due to MS) in 0.5-point increments, providing a structured framework for evaluating functional limitations. The primary purpose of the EDSS is to offer an objective, standardized method for tracking disease progression and assessing treatment outcomes in , making it a cornerstone for monitoring in clinical settings and as a key endpoint in clinical trials. By focusing on clinically observable impairments, the scale enables healthcare providers to benchmark levels over time and evaluate therapeutic interventions. At its core, the EDSS integrates evaluations of across eight functional systems—such as pyramidal, cerebellar, and sensory—with an assessment of overall ability to derive a composite score that captures the multifaceted nature of MS-related . While specifically tailored for , the EDSS has been occasionally applied to other neurological contexts, including the assessment of age-related in older adults without , highlighting its broader utility in quantifying functional deficits.

History and Development

The Expanded Disability Status Scale (EDSS) originated from the efforts of neurologist John F. Kurtzke, who worked extensively with (MS) patients at the Veterans Administration in the mid-20th century. Building on earlier qualitative classification systems for MS, such as those proposed in the 1940s and 1950s that relied on broad symptomatic descriptions without standardized quantification, Kurtzke sought to create a more objective measure of disability to facilitate and patient assessment. His initial contribution was the Disability Status Scale (DSS), a 10-step ordinal ranging from 0 (normal) to 10 (death due to MS), first described in 1955 to evaluate overall physical disability based primarily on ambulatory function. This addressed the limitations of prior methods by providing a simple, reproducible framework, though it lacked detailed breakdown of neurological impairments. Kurtzke refined the DSS in subsequent publications, including a 1961 that expanded its application to incorporate more comprehensive evaluations of neurological involvement, emphasizing the need for quantifiable metrics in tracking disease progression among veterans. By 1970, he introduced the concept of Functional Systems (), delineating eight key domains of neurological function—such as pyramidal, cerebellar, and sensory systems—to grade impairments on a 0-to-5 or 6 scale, allowing for a more granular of MS-related deficits. These FS scores complemented the DSS by shifting from purely ambulatory-focused evaluations to a multifaceted view of impairment, enabling better correlation between specific symptoms and overall disability in longitudinal studies of veterans with . This evolution marked a transition from subjective, qualitative assessments to semi-quantitative tools, improving and suitability for multicenter research. The EDSS emerged in 1983 as Kurtzke's expansion of the DSS, integrating the FS scores to create a 20-step (0 to 9.5 in 0.5 increments) that balanced detailed functional grading with overall disability ranking, particularly emphasizing walking ability for higher scores. Published in the Neurology, this seminal work formalized the EDSS as a standardized , rapidly establishing it as the gold standard for assessing neurological impairment in clinical trials due to its ability to capture progressive disability in a reproducible manner across diverse study populations. The 's design addressed prior gaps in sensitivity for early disease stages while maintaining simplicity for practical use in research settings.

Assessment Components

Functional Systems

The functional systems assessment in the Expanded Disability Status Scale (EDSS) evaluates neurological impairments across eight distinct domains, derived from a standardized performed by a trained . Each system is scored independently on an ordinal typically ranging from 0 ( function) to 5 or 6 (severe or maximal ), depending on the , with scores reflecting the degree of dysfunction based on findings and patient history. These evaluations provide a granular view of multiple sclerosis-related deficits, though the systems are assessed separately and only indirectly influence the overall EDSS score through their effects on ambulatory ability. Pyramidal system assesses motor function, focusing on limb strength, , and pyramidal tract involvement. Scoring ranges from 0 () to 6 (quadriplegia or complete loss of motor function), determined via manual muscle testing, reflex examination, and evaluation of gait abnormalities attributable to weakness. Mild might involve subtle without functional limitation, while higher scores indicate progressive limb involvement leading to significant mobility restrictions. Cerebellar system evaluates coordination, balance, and . Scores go from 0 (normal) to 5 (inability to perform coordinated movements due to ), assessed through tests such as finger-to-nose, heel-to-shin, and rapid alternating movements. Early impairment may present as mild limb without , escalating to severe truncal instability that markedly affects daily activities. Brainstem system examines cranial nerve functions and brainstem integrity, including eye movements, facial sensation, swallowing, and speech. It is scored from 0 (normal) to 5 (complete inability to swallow or speak), using observations of , extraocular movements, and oropharyngeal function. Moderate scores often reflect issues like unilateral facial weakness or mild , while severe impairment involves bilateral cranial nerve deficits. Sensory system gauges impairments in , such as touch, , , and . Scoring spans 0 (normal) to 6 (essential loss of sensation below the head), via pinprick, light touch, joint position sense, and vibration testing across dermatomes. Initial abnormalities might include isolated vibration loss in the lower limbs, progressing to marked or numbness causing functional challenges like falls. Bowel and bladder system assesses sphincter control and urinary/bowel dysfunction. It ranges from 0 (normal) to 5 (total loss of function), based primarily on patient-reported symptoms corroborated by examination, such as hesitancy, urgency, retention, or incontinence frequency. Mild issues involve occasional urgency without leakage, whereas higher scores indicate needs for catheterization or persistent incontinence impacting . Visual system evaluates optic nerve and visual pathway integrity, including acuity and field defects often due to optic neuritis. Scores are from 0 (normal) to 6 (maximal visual acuity less than 20/200 in the worse eye and 20/60 or worse in the better eye, indicating severe bilateral impairment), measured with Snellen charts, color vision tests, and visual field perimetry. A score of 1 might represent a unilateral scotoma with good recovery, while severe levels denote bilateral vision loss limiting independence. Cerebral system covers cognitive function, mood, and mental status changes. It is scored from 0 (normal) to 5 ( or severe chronic brain syndrome), through brief cognitive screening, orientation tests, and assessment of affect. Non-specific symptoms like , , or mild memory lapses score low if they do not impair daily function, but moderate to severe cognitive decline affects problem-solving and emotional regulation. Other system captures miscellaneous neurological impairments not fitting into the prior categories, such as paroxysmal symptoms, pain, or fatigue attributed to multiple sclerosis. Scoring is from 0 (none) to 1 (any other neurologic findings attributed to MS, which must be specified), relying on clinical judgment and symptom history. This domain accommodates unique presentations without further gradation, ensuring comprehensive coverage of deficits; a score of 1 minimally affects overall disability assessment.

Ambulatory Function

The ambulatory function in the Expanded Disability Status Scale (EDSS) evaluates a patient's walking ability as the primary determinant of levels from 0 to 7, emphasizing mobility as the scale's central metric and overriding assessments of other functional systems in this range. This assessment focuses on the distance a patient can walk without rest, initially without aids for lower scores and incorporating assistive devices for higher ones, providing a direct measure of lower limb in . For EDSS scores of 0 to 4.0, patients are fully without aids, with the ability to walk at least 500 meters without rest defining the 4.0 threshold; scores below this level differentiate based on the extent of neurological impairment affecting , though walking remains unlimited in practice. At 4.5, unaided walking is limited to 300 meters without rest, indicating moderate restrictions in daily activities due to or coordination issues. Progression to 5.0 and 5.5 further restricts unaided walking to 200 meters and 100 meters, respectively, without rest, reflecting severe that precludes full normal activities despite remaining . From EDSS 6.0 onward, assistive devices become integral to the evaluation, marking a shift to dependent . At 6.0, patients can walk 100 meters using intermittent or unilateral aids such as a single , , or , combining impairments across multiple functional systems. The 6.5 level requires constant bilateral support (e.g., two s or a ) to cover just 20 meters, underscoring significant paraparesis. By 7.0, walking is confined to about 5 meters with any aid, with patients otherwise wheelchair-bound but able to self-propel for up to 12 hours daily. These thresholds highlight how the introduction and type of assistive devices— from unilateral to bilateral supports and eventually wheelchairs—directly influence scoring, prioritizing practical over isolated neurological deficits.

Scoring and Interpretation

EDSS Score Calculation

The Expanded Disability Status Scale (EDSS) is derived through a structured process that integrates scores from the eight functional systems (FS) with an assessment of ambulatory function, resulting in a composite score ranging from 0 (normal neurological examination) to 10 (death due to multiple sclerosis [MS]) in half-point increments, yielding 21 possible scores overall. The calculation begins by evaluating each of the eight FS—pyramidal, cerebellar, , sensory, bowel and , visual, cerebral or mental, and other—on a from 0 () to 5 or 6 (severe impairment), depending on the system, through a standardized that assesses signs and disability levels. Next, ambulatory function is determined by measuring the distance a patient can walk without rest or aid (typically up to 500 meters) or the assistance required for shorter distances, which primarily reflects pyramidal system impairment but incorporates overall mobility. Certain FS scores, such as visual (capped at 4 for EDSS purposes) and bowel/ (capped at 5), are converted downward if higher to avoid overemphasizing isolated deficits. For EDSS scores of 0 to 3.5, the patient must be fully (able to walk at least 500 meters without aid), and the composite score is assigned based on the highest score or combinations thereof, with the pyramidal score taking precedence if it exceeds impairments in other systems; for instance, a single score of 3 with others at 0 or 1 yields 3.0, while multiple moderate impairments (e.g., three to four at 2) may reach 3.0 or 3.5. In contrast, for scores of 4.0 to 9.5, the EDSS primarily reflects restrictions, with the whole-number steps defined by walking distance or aid needs (e.g., 4.0 for ≥500 meters unaided, 4.5 for 300–499 meters unaided, 5.0 for 200–299 meters unaided, 5.5 for 100–199 meters unaided, 6.0 for ≥100 meters with unilateral aid, 6.5 for 20–99 meters with bilateral aid), and half-steps (.5) added only if impairments meet specific thresholds, such as two or more at grade 3 or higher (e.g., one at grade 4 with others ≤1 for certain half-steps). This creates a "plateau" effect, particularly in scores 4.0 to 7.0, where ability dominates the rating, and contribute nuance primarily at half-step boundaries rather than altering the core level. For the highest levels, scores of 8.0 to 9.5 are determined solely by the degree of confinement to or chair and level of dependence, independent of lower FS details: 8.0 indicates restriction to or chair but ability to perform with arms; 8.5 involves -bound status for much of the day with limited arm function; 9.0 denotes a helpless who can still communicate and eat; and 9.5 reflects total helplessness, including inability to communicate or swallow effectively. The terminal score of 10 is assigned only upon death due to .

Score Levels and Clinical Significance

The Expanded Disability Status Scale (EDSS) ranges from 0 to 10, with scores reflecting increasing levels of neurological impairment and in (), primarily emphasizing function at higher levels. A score of 0 indicates a normal with no . Scores from 1.0 to 3.5 represent mild , where individuals experience minimal to moderate signs in one or more functional systems but remain fully without aid and can walk unlimited distances. From 4.0 to 5.5, moderate emerges, with ability ranging from ≥500 meters (4.0) to 100 meters (5.5) without assistance, though patients are still self-sufficient in daily activities. Scores of 6.0 to 6.5 denote severe , requiring unilateral or bilateral aid to walk 20–100 meters. At 7.0, patients are wheelchair-bound but able to self-propel and perform most ; higher scores from 7.5 to 9.5 indicate progressive dependence, with confinement to bed or chair for most of the day and varying needs for assistance in , communication, and hygiene. A score of 10 signifies death due to . Clinically, EDSS scores below 4.0 typically correspond to early-stage with preserved overall function and minimal impact on , allowing patients to maintain and . In contrast, scores exceeding 6.0 signal advanced disease, often associated with substantial care needs, reduced mobility, and heightened risk of complications such as infections or pressure sores. These thresholds help clinicians gauge , as progression to EDSS 6.0 (requiring a walking aid) marks a critical transition to significant . EDSS progression in relapsing-remitting occurs at an average rate of approximately 0.14 points per year in untreated patients, reflecting gradual accumulation of irreversible deficits beyond relapses. In clinical trials evaluating disease-modifying therapies, a sustained 1-point increase confirmed over 6 months is considered clinically meaningful, indicating meaningful worsening that impacts patient function and justifies therapeutic adjustments.
EDSS Score RangeDescription of Disability Level
0Normal; no disability.
1.0–3.5Mild; fully ambulatory, unlimited walking distance.
4.0–5.5Moderate; ambulatory without aid, ≥100–≥500 m.
6.0–6.5Severe; requires unilateral or bilateral aid to walk 20–100 m.
7.0Wheelchair-bound; self-mobile and independent in most activities.
7.5–9.5Bedridden; increasing dependence on others for care.
10Death due to MS.

Clinical Applications and Limitations

Use in Multiple Sclerosis Management

The Expanded Disability Status Scale (EDSS) plays a central role in the clinical management of multiple sclerosis (MS) by providing a standardized method for baseline assessment and ongoing monitoring of neurological disability. Clinicians use the EDSS to evaluate a patient's initial disease burden at diagnosis and track changes during follow-up visits, enabling the detection of progression or treatment response over time. This serial evaluation informs decisions on initiating or adjusting disease-modifying therapies (DMTs), particularly in relapsing-remitting MS (RRMS) and primary progressive MS (PPMS), where early intervention aims to preserve function before significant impairment accumulates. For instance, the EDSS helps stratify patients for DMT eligibility, such as recommending therapies for those with mild disability to prevent worsening. In research settings, the EDSS is a cornerstone , frequently serving as the primary in phase III clinical trials to assess the of novel therapies. A prominent example is the ORATORIO trial, which evaluated ocrelizumab in PPMS and used 12-week confirmed progression on the EDSS—defined as a sustained increase of at least 1 point (or 1.5 points from a of 0)—as the main , demonstrating a 24% risk reduction with treatment compared to . Observational studies and registries further leverage the EDSS for ; the MSBase international registry, for example, collects over 550,000 EDSS scores as of 2019 to analyze long-term trajectories, treatment effectiveness, and predictors of progression across diverse patient populations. Professional guidelines integrate the EDSS for staging MS severity and standardizing care protocols. The National MS Society endorses its use in clinical study measures and patient management to benchmark disability and guide therapeutic strategies, emphasizing regular assessments to inform personalized treatment plans. Additionally, confirmed disability progression (CDP) via serial EDSS measurements—such as a ≥1.0-point increase (or ≥1.5 points from baseline 0) sustained for 6 months in patients with baseline scores of 1.0–5.5, or ≥0.5 points for baseline ≥6.0—serves as a key indicator for escalating or evaluating control.

Criticisms and Reliability Issues

The Expanded Disability Status Scale (EDSS) has been criticized for its moderate reliability, particularly in terms of inter-rater variability. Studies have reported inter-observer kappa scores ranging from 0.32 to 0.76, indicating only moderate agreement between different examiners, with greater variability observed at lower EDSS scores (1.0-3.5). Intra-rater reliability is somewhat higher but remains variable, and interrater differences exceeding 1 point on the EDSS scale occur in up to 40% of cases. These issues stem from the subjective nature of assessing functional systems and ambulatory ability, which can lead to inconsistent scoring across clinicians. A primary criticism of the EDSS is its overemphasis on ambulatory function, which largely ignores deficits in upper limb function, cognition, and other non-motor domains affected in multiple sclerosis (MS). This focus results in a ceiling effect at higher scores (EDSS 6.0-10.0), where granularity is lost as scores plateau despite significant progression in wheelchair dependence or bedridden states, limiting its utility for advanced disease. Conversely, a floor effect is evident at lower scores (EDSS 0-3.5), where subtle impairments are not adequately captured, reducing sensitivity to early changes. Additionally, the scale may not fully account for age-related comorbidities in older individuals. The EDSS is also noted for its insensitivity to subtle clinical changes, particularly in short-term clinical trials, where only about 20% of patients demonstrate measurable progression. This low detection rate hampers its responsiveness in early or relapsing-remitting , where non-ambulatory symptoms predominate, and underscores the need for complementary measures to track disease activity more comprehensively.

Modified Versions and Updates

The Neurostatus-EDSS, developed in the early 1990s by Ludwig Kappos and colleagues at the , represents a key modification to the original EDSS by incorporating detailed, quantified definitions for neurological examinations and mandatory structured training for raters. This version evaluates seven functional systems—pyramidal, cerebellar, , sensory, bowel and bladder, visual, and cerebral—alongside ambulation, aiming to mitigate the original scale's variability in subjective assessments. is notably enhanced, with studies reporting kappa coefficients exceeding 0.8 for subscores and overall EDSS steps. To further standardize administration and reduce inconsistencies, Neurostatus Systems provides comprehensive training programs, including interactive e-tests and certification for over 9,000 examiners worldwide since 2004, which have been integral to multi-center MS trials. These programs emphasize precise scoring protocols, directly addressing the original EDSS's moderate inter-rater reliability issues through rigorous, reproducible methods. Digital advancements began with the introduction of the Neurostatus-eEDSS in 2011, an electronic tool that automates data capture and delivers real-time feedback on scoring errors, resulting in fewer inconsistencies and higher assessment quality in clinical trials. Post-2020 developments, such as the Neurostatus-SMARTCARE platform, extend this by enabling remote evaluations via mobile apps and video-based reviews, supporting decentralized trials while maintaining concordance with in-clinic Neurostatus-EDSS scores. Integrating EDSS with emerging technologies, a 2021 study by Piryonesi et al. utilized machine learning algorithms incorporating EDSS scores alongside other clinical data to predict falls and related injuries in MS patients, achieving high predictive accuracy and highlighting the scale's potential in AI-driven risk assessment.

Comparisons to Other Disability Scales

The Expanded Disability Status Scale (EDSS) is often compared to the Timed 25-Foot Walk (T25FW), an objective performance-based measure that assesses walking speed over a short distance, typically used to evaluate lower limb function in multiple sclerosis (MS) patients. Unlike the EDSS, which incorporates a broad range of neurological impairments across multiple functional systems, the T25FW focuses narrowly on ambulatory mobility and has demonstrated greater sensitivity in detecting early changes in relapsing-remitting MS (RRMS) and primary progressive MS (PPMS) clinical trials. For instance, analyses of trial datasets indicate that the T25FW identifies progression more reliably than the EDSS in ambulatory patients, though it lacks the comprehensive scope of the EDSS for overall disability assessment. Another key alternative is the MS Functional Composite (MSFC), a multidimensional tool that integrates the T25FW for walking, the 9-Hole Peg Test for upper limb dexterity, and the Paced Auditory Serial Addition Test for cognitive processing speed. Developed to address the EDSS's limitations in evaluating arm function and cognition, the MSFC provides a more balanced evaluation of physical and cognitive impairments in MS, showing stronger correlations with brain parenchymal fraction and better sensitivity to short-term changes compared to the EDSS alone. Systematic reviews confirm that while both scales are valid for monitoring disease progression and treatment effects, the MSFC's composite nature makes it particularly useful for capturing subtle deteriorations in diverse domains that the clinician-rated EDSS may overlook. Patient-reported outcome measures, such as the Short Form-36 Health Survey () and the Multiple Sclerosis Impact Scale-29 (MSIS-29), differ fundamentally from the EDSS by emphasizing health-related (HRQOL) from the patient's perspective rather than clinician-observed physical disability. The is a generic instrument assessing general physical and components, while the MSIS-29 is MS-specific, focusing on the physical and psychological impacts of the disease; both have been validated in progressive MS cohorts but show weaker correlations with EDSS scores, highlighting their complementary role in capturing subjective experiences like and emotional that the EDSS does not address. Despite these alternatives, the EDSS remains the gold standard for clinical trials due to its extensive historical dataset and established role in regulatory approvals, though composite measures like the MSFC are gaining prominence for more holistic evaluations in modern research. This shift reflects ongoing recognition of the EDSS's limitations in sensitivity for cognitive and functions, as noted in prior critiques.

References

  1. [1]
    Rating neurologic impairment in multiple sclerosis - PubMed
    A new Expanded Disability Status Scale (EDSS) is presented, with each of the former steps (1,2,3 . . . 9) now divided into two (1.0, 1.5, 2.0 . . . 9.5).Missing: original | Show results with:original
  2. [2]
    Kurtzke Expanded Disability Status Scale - Multiple Sclerosis ...
    The EDSS provides a total score on a scale that ranges from 0 to 10. The first levels 1.0 to 4.5 refer to people with a high degree of ambulatory ability and ...
  3. [3]
    Expanded Disability Status Scale (EDSS) - MS Society
    The Expanded Disability Status Scale (EDSS) is a way of measuring how much someone is affected by their MS. Neurologists use it to monitor changes in the level ...
  4. [4]
    Systematic literature review and validity evaluation of the Expanded ...
    Mar 25, 2014 · The EDSS is used to describe disease progression in patients with MS and to assess the effectiveness of therapeutic interventions in clinical ...
  5. [5]
    What is the Expanded Disability Status Scale really telling clinicians?
    Dec 28, 2020 · Older individuals with and without MS demonstrated significant disability on the EDSS. These findings indicate that EDSS scores may be ...Missing: adults | Show results with:adults
  6. [6]
    A New Scale for Evaluating Disability in Multiple Sclerosis | Neurology
    A New Scale for Evaluating Disability in Multiple Sclerosis. John F. Kurtzke, M.D.Authors Info & Affiliations. August 1955 issue. 5 (8) 580. https://doi.org ...
  7. [7]
    On the evaluation of disability in multiple sclerosis - Neurology.org
    Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). [...] John F. Kurtzke; +0 authors. Neurology. Article. 1 Jul ...
  8. [8]
    NEUROLOGIC IMPAIRMENT IN MULTIPLE SCLEROSIS AND THE ...
    One system used includes the delineation of overall neurologic dysfunction according to a Disability Status Scale which is scored on a 0 to 10 basis, with 0 ...
  9. [9]
    Rating neurologic impairment in multiple sclerosis
    Nov 1, 1983 · Rating neurologic impairment in multiple sclerosis. An expanded disability status scale (EDSS). John F. Kurtzke, MDAuthors Info & Affiliations.Missing: PMID | Show results with:PMID
  10. [10]
    Kurtzke's Expanded Disability Status Scale (EDSS) - NCBI - NIH
    Kurtzke JF. 1983. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology.;33:1444-52.
  11. [11]
    [PDF] The Expanded Disability Status Scale (EDSS) - edmus
    4.5. Fully ambulatory without aid, up and about much of the day, able to work a full day, may otherwise have some limitation of full activity or require minimal.
  12. [12]
    [PDF] SPECIMEN - Neurostatus.net
    when determining the EDSS step, the Visual FS score must be converted to a lower score as follows: Visual FS Score. 6. 5. 4. 3. 2. 1 converted Visual FS Score.
  13. [13]
    Expanded Disability Status Scale (EDSS) - MS Trust
    Oct 14, 2024 · The Expanded Disability Status Scale measures your current level of disability. Neurologists use it to benchmark and monitor changes in ...
  14. [14]
    [PDF] Expanded Disability Status Scale (EDSS) in Multiple Sclerosis
    Dec 15, 2022 · Kurtzke (11). ... Interrater variability with the Expanded Disability Status Scale (EDSS) and. Functional Systems (FS) in a multiple sclerosis ...
  15. [15]
    Estimating the rates of disability progression in people with active ...
    In addition, in. MS randomised controlled trials, the concept of 'confirmed progression' is standard practice, with EDSS levels required to increase by 1.0 ...<|control11|><|separator|>
  16. [16]
    Confirmed disability progression as a marker of permanent disability ...
    May 18, 2022 · Relapsing–remitting multiple sclerosis with EDSS score <6, First progression event only. Age, years, −0.018 (−0.026, −0.010)***, −0.019 ...
  17. [17]
    [PDF] National MS Society Information Sourcebook
    The Expanded Disability Status Scale or EDSS is one of the oldest and most widely used rating systems for judging the clinical status of people with MS. Uses ...Missing: management | Show results with:management
  18. [18]
    [PDF] Disease-modifying Therapies for Adults with Multiple Sclerosis
    Apr 24, 2018 · This practice guideline reflects the complexity of decision making when considering initiating, switching, or stopping DMT use for MS. The ...
  19. [19]
    Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
    Dec 21, 2016 · Among patients with primary progressive multiple sclerosis, ocrelizumab was associated with lower rates of clinical and MRI progression than placebo.
  20. [20]
    [PDF] The MSBase registry: Informing clinical practice - Monash
    Oct 28, 2017 · In March 2019, it has held almost 550,000 disability scores (Expanded Disability Status Scale. (EDSS)), 86% of which also had recorded Kurtzke.
  21. [21]
    FSS and EDSS Assessment for MS | National MS Society
    The FSS and EDSS are ordinal clinical rating scales that are rated on the basis of the judgment of the examiner. Each of the FSS and the EDSS are single-item ...<|control11|><|separator|>
  22. [22]
    Greater sensitivity to multiple sclerosis disability worsening and ...
    Approximately 70% more EDSS progression events unrelated to relapse and 50% more EDSS worsening events overall were detected with a roving reference score ( ...
  23. [23]
    Systematic literature review and validity evaluation of the Expanded ...
    Mar 25, 2014 · The EDSS is used to describe disease progression in patients with MS and to assess the effectiveness of therapeutic interventions in clinical ...
  24. [24]
    Expanded Disability Status Scale - an overview | ScienceDirect Topics
    The EDSS has been used to provide an index of functional disability in MS patients from the 1980s (Kurtzke, 1983) to the present day (National Multiple ...
  25. [25]
    [PDF] Enhancing the Accuracy of Disability Measurement - bac-lac.gc.ca
    The EDSS has been criticized for well known psychometric limitations, a narrow representation of disability, and an over emphasis on ambulation. There is a ...
  26. [26]
    Disability status and quality of life in multiple sclerosis: non-linearity ...
    Jun 7, 2010 · Progression in disability as measured by increase in the Expanded Disability Status Scale (EDSS) is commonly used as outcome variable in ...Quality Of Life · Table 2 · Discussion<|control11|><|separator|>
  27. [27]
    Evaluation of multiple sclerosis disability outcome measures using ...
    LCLA distribution appeared mildly negatively skewed without floor or ceiling effects. SDMT scores showed no evidence of skewing, or floor or ceiling effects.Abstract · Outcome Measures · Discussion
  28. [28]
    Disability Outcome Measures in Phase III Clinical Trials in Multiple ...
    Jun 20, 2018 · Sustained EDSS worsening over short time periods continues to be the most widely used measure of disability progression in pivotal MS trials.Outcome Measures Assisting... · 3 Results · 4 Discussion
  29. [29]
    Neurostatus-UHB - Universitätsspital Basel
    The Neurostatus-EDSS scale was first introduced in the early 1990s by Professor Ludwig Kappos and his team at the University Hospital Basel, as part of an MS ...
  30. [30]
    Neurostatus e-Scoring improves consistency of Expanded Disability ...
    Our data provide class II evidence that the use of NESC increases consistency of standardized EDSS assessments, and may thus have the potential to decrease ...
  31. [31]
    about Neurostatus and EDSS
    Since 2004 the Neurostatus e-Test has been used worldwide to certify more than 9000 EDSS examiners participating in nearly all multi-centre studies conducted ...Missing: introduction | Show results with:introduction<|control11|><|separator|>
  32. [32]
    Electronic Neurostatus-EDSS increases the quality of expanded ...
    The Neurostatus-eEDSS is an electronic tool providing automated real-time feedback on inconsistencies of Neurostatus-EDSS calculations.Missing: 2011 | Show results with:2011
  33. [33]
  34. [34]
    Neurostatus-SMARTCARE clinical trial - Sage Journals
    Dec 20, 2024 · Trained HCPs can reliably perform Neurostatus-EDSS assessments, supporting broader implementation and improved trial access. Introduction.Study Design · Study Population · DiscussionMissing: post- | Show results with:post-
  35. [35]
    Predicting falls and injuries in people with multiple sclerosis using ...
    We used historical data and machine learning algorithms to predict three outcomes: falling, sustaining injuries and injury types caused by falling in PwMS. The ...Missing: et AI
  36. [36]
    Comparison of the EDSS, Timed 25-Foot Walk, and the 9-Hole Peg ...
    Oct 19, 2021 · Our analyses raise concerns about using the EDSS as the standard disability outcome in RRMS trials and suggest that the T25FW may be a more useful measure.
  37. [37]
    The timed 25-foot walk is a more sensitive outcome measure than ...
    May 16, 2022 · The timed 25-foot walk is a more sensitive outcome measure than the EDSS for PPMS trials: an analysis of the PROMISE clinical trial dataset.Missing: comparison | Show results with:comparison
  38. [38]
    Development of a multiple sclerosis functional composite as a ...
    This too might lead to reduced sensitivity and specificity in detecting EDSS change, suggesting that the composite does not adequately detect change over ...Missing: subtle | Show results with:subtle
  39. [39]
    The value of patient-reported outcome measures for multiple sclerosis
    Sep 1, 2022 · The SF-36 is a generic measure to assess health-related quality of life (HRQOL); whereas the MSIS-29 is a condition-specific PROM evaluating ...
  40. [40]
    The MSIS-29 and SF-36 as outcomes in secondary progressive MS ...
    Higher scores on MSIS-29 indicate worse HRQOL, and higher scores on the SF-36 indicate better HRQOL.